Barclays Maintains Equal-Weight on Pfizer, Lowers Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould has maintained an Equal-Weight rating on Pfizer (NYSE:PFE) but has reduced the price target from $34 to $28.
December 14, 2023 | 11:41 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays has maintained an Equal-Weight rating on Pfizer but lowered the price target from $34 to $28, indicating a more cautious outlook on the stock's value.
The reduction in price target by a major financial institution like Barclays can lead to a negative perception among investors regarding Pfizer's future stock performance. This could result in short-term downward pressure on the stock price as the market adjusts to the new price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100